hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06299943 id: BiofeedbackTargetGaitTraining briefTitle: Biofeedback Gait Training by Target Biomechanical Parameters in the Early Recovery Period of Stroke acronym: TargetGait overallStatus: RECRUITING date: 2022-01-24 date: 2025-12-30 date: 2025-12-30 date: 2024-03-08 date: 2024-03-12 name: Federal Center of Cerebrovascular Pathology and Stroke, Russian Federation Ministry of Health class: OTHER briefSummary: Single-blinded controlled clinical trial. Biofeedback training courses based on target biomechanical gait parameters are being studied. For targeted biofeedback training, various biomechanical parameters are used: parameters of the gait cycle, EMG or kinematics of joint movements. The number of sessions is 8-11 for each patient. Clinical gain analysis is carried out before and after a course of training. Changes in biomechanical parameters that occurred at the end of the training course are assessed in comparison with those before training, and both statuses (before and after training) are compared with similar gait parameters in a group of healthy adults. conditions: Stroke conditions: Biofeedback conditions: Gait, Hemiplegic conditions: Gait Training conditions: Hemiparesis studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Parallel-group, single-blinded controlled clinical trial. primaryPurpose: TREATMENT masking: QUADRUPLE maskingDescription: Clinicians involved in the measurements and researchers that worked with data results did not know which group each patient was in. whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 120 type: ESTIMATED name: Biofeedback gait training by biomechanical target parameter measure: Gait cycle measure: Foot clearance measure: Speed of walking measure: Stance phase measure: Single support phase measure: Hip joint amplitude measure: Knee joint amplitude measure: Ankle joint amplitude measure: EMG amplitude of tibialis anterior muscle measure: EMG amplitude of gastrocnemus muscle measure: EMG amplitude of quadriceps femoris muscle measure: EMG amplitude of Hamstring muscle measure: Muscle strength measure: Activities of Daily Living measure: Modified Rankin Scale for Neurologic Disability measure: The Timed Up and Go Test measure: The Medical Research Council Weakness Scale sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: FCCerebroPathStroke status: RECRUITING city: Moscow zip: 117997 country: Russian Federation name: Dmitry Skvortsov, PhD role: CONTACT phone: +79166925419 email: skvortsov.biom@gmail.com lat: 55.75222 lon: 37.61556 hasResults: False
nctId: NCT06299930 id: LRR after NACT vs ACT briefTitle: Locoregional Recurrence After Neoadjuvant Versus Adjuvant Chemotherapy overallStatus: COMPLETED date: 2022-04-22 date: 2023-08-16 date: 2023-09-12 date: 2024-03-08 date: 2024-03-08 name: Seoul National University Hospital class: OTHER briefSummary: Neoadjuvant chemotherapy (NACT) for early-stage breast cancer is associated with an increased risk of locoregional recurrence (LRR). However, few studies have conducted subgroup analyses of patients with various molecular subtypes, which are one of the determinant factors for treatments. The aim of the study is to investigate whether the risk of LRR after NACT varies across tumor subtypes. The investigators retrospectively reviewed the medical records of female breast cancer patients who underwent breast-conserving surgery at three institutions between January 1, 2004, and Dec 31, 2018. conditions: Breast Cancer studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: RETROSPECTIVE count: 10328 type: ACTUAL name: Neoadjuvant chemotherapy name: Adjuvant chemotherapy measure: Locoregional recurrence-free survival (LRR) measure: Distant metastasis-free survival sex: FEMALE minimumAge: 18 Years maximumAge: 100 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Seoul National University Hospital city: Seoul zip: 03080 country: Korea, Republic of lat: 37.566 lon: 126.9784 typeAbbrev: Prot_SAP hasProtocol: True hasSap: True hasIcf: False label: Study Protocol and Statistical Analysis Plan date: 2022-04-22 uploadDate: 2024-03-01T20:58 filename: Prot_SAP_000.pdf size: 151396 hasResults: False
nctId: NCT06299917 id: CeViG id: S-20232000 - 3 type: OTHER domain: Committees on Health Research Ethics for Southern Denmark briefTitle: WORK-ON Vocational Rehabilitation for People With Inflammatory Arthritis acronym: WORK-ON overallStatus: RECRUITING date: 2024-03-01 date: 2027-09-01 date: 2027-09-01 date: 2024-03-08 date: 2024-04-17 name: The Danish Center for Expertise in Rheumatology class: OTHER name: Odense Patient Data Explorative Network name: The Danish Rheumatism Association name: Danish Association of Occupational Therapist name: Schaufuss foundation briefSummary: People with chronic inflammatory arthritis (IA) (rheumatoid arthritis, axial spondyloarthritis, and psoriatic arthritis), often have a reduced work ability. Up to 40% lose their job in the first years after diagnosis. Consequently, they are at high risk of losing their jobs and being permanently excluded from the labour market. Therefore, a new context-specific vocational rehabilitation (VR) for people with IA was developed, based on the Medical Research Council's framework for complex interventions. The 6-months VR is called WORK-ON and consists of three parts: 1) a coordinating occupational therapist who performs an initial assessment and goalsetting process and supports cooperation between relevant partners and navigation between sectors, 2) Four group sessions with peers and if needed, 3) Individual sessions with a social worker, nurse, or physiotherapist. The objective of the WORK-ON trial is to test the overall efficacy on work ability compared to a control group who receives usual care and pamphlets for their employer and colleagues.
Based on the experiences from a feasibility study, WORK-ON will be conducted as a randomised controlled trial. Patients with IA, aged 18 years or older, experiencing job insecurity will be randomised to one of two groups: the WORK-ON VR group or usual care (control group). The primary outcome; work ability measured is measured by Work Ability Index single item, at baseline, 6, 12, 18 and 30 months after baseline. Secondary outcomes are absenteeism, presenteeism, overall work impairment, activity impairment, job loss, quality of life, mental well-being, fatigue, sleep, physical activity, occupational balance and pain. Secondary outcomes are measured at baseline, 6 and 12 months after baseline. In addition, work ability, working hours per week and job loss are measured at 18 and 30 months after baseline. conditions: Rheumatoid Arthritis conditions: Psoriatic Arthritis conditions: Axial Spondyloarthritis studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Single center parallel randomized study primaryPurpose: OTHER masking: NONE maskingDescription: Statistical analyses will be blinded for group allocation count: 56 type: ESTIMATED name: WORK-ON measure: Work Ability Index (WAI) single item measure: Job loss measure: Work hours per week measure: Work Productivity and Activity Impairment questionnaire, general health (WPAI:GH) measure: Sickness absenteeism measure: Work ability in relation to demands measure: Job insecurity measure: Physical activity while at work measure: Occupational balance measure: Health related quality of life measure: VAS Pain measure: Fatigue measure: Physical activity measure: Mental well-being measure: Sleep measure: Work Ability Index (WAI) single item sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Danish Hospital for Rheumatic Diseases status: RECRUITING city: Sønderborg zip: 6400 country: Denmark name: Christina MT Madsen, MSci role: CONTACT phone: +4528551373 email: cmadsen@danskgigthospital.dk name: Jette Primdahl, PhD role: CONTACT phone: +4524206692 email: jprimdahl@danskgigthospital.dk lat: 54.90896 lon: 9.78924 hasResults: False
nctId: NCT06299904 id: stroke briefTitle: Effect of Modified Air-pulse Stimulation on Tracheotomised Patients With Dysphagia After Stroke overallStatus: RECRUITING date: 2023-12-01 date: 2024-12-01 date: 2024-12-01 date: 2024-03-08 date: 2024-03-08 name: The Second Affiliated Hospital of Dalian Medical University class: OTHER briefSummary: To evaluate the efficacy of flexible endoscopy-mediated modified air-pulse stimulation in restoring of swallowing function in this group of patients.Forty-two subacute stroke patients with tracheotomy and dysphagia need to be recruited and divided into a control group of 21 cases and a trial group of 21 cases. On the basis of receiving personalized swallowing rehabilitation training, the control group received traditional air-pulse stimulation therapy, while the trial group received modified air-pulse stimulation therapy mediated by flexible endoscopy. Murray secretion scale (MSS), penetration-aspiration scale (PAS) and spontaneous swallowing frequency were used to assess dysphagia. Moreover, clinical pulmonary infection score (CPIS) was used for evaluating the degree of pneumonia, hemoglobin(Hb) and serum prealbumin (PAB) were used to assess the nutritional status of patients. conditions: Stroke studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: PARTICIPANT count: 42 type: ESTIMATED name: Modified Air-pulse Stimulation name: Conventional air-pulse stimulation measure: the score of Fiberoptic endoscopic examination of swallowing (FEES) measure: the score of Murray's secretion scale (MSS) measure: the score of penetration-aspiration scale (PAS) measure: the score of Clinical Pulmonary Infection Score (CPIS) sex: ALL minimumAge: 30 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: the Second Affiliated Hospital of Dalian Medical University status: RECRUITING city: Dalian state: Liaoning zip: 116024 country: China name: wuyao Pan, postgraduate role: CONTACT phone: +86-18186766836 email: 331189506@qq.com lat: 38.91222 lon: 121.60222 hasResults: False
nctId: NCT06299891 id: PhT_HypOb_Protocol_Clean_07-05 briefTitle: Efficacy and Safety of Phentermine/Topiramate in Youth With Hypothalamic Obesity overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2026-05-31 date: 2026-05-31 date: 2024-03-08 date: 2024-04-16 name: Seattle Children's Hospital class: OTHER name: Children's Hospital of Philadelphia briefSummary: Hypothalamic obesity (HO) refers to the substantial weight gain that often complicates hypothalamic brain tumors. Children with this treatment-recalcitrant form of obesity have excess rates of metabolic sequelae compared to otherwise healthy children with similar obesity, and later experience excess mortality related to cardiometabolic disease. In this pilot trial, our objective is to gather key preliminary data about phentermine/topiramate (Ph/T) that is FDA-approved for "common" obesity but has never been tested in HO. The subset of individuals with HO who experience hyperphagia or excess daytime sleepiness may benefit from the Ph/T-induced decrease in appetite and increase in alertness.
Preliminary assessments of safety, adverse events, dosing (Aim 1), as well as of efficacy (% BMI loss, Aim 2) will be made in a 28-week parallel-arm double-blinded Phase 2 placebo-controlled clinical trial in 12-28-year-old individuals with HO. conditions: Hypothalamic Obesity conditions: Hypothalamic Tumor conditions: Craniopharyngioma studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Two-center, double-blind (participant and assessor), randomized, parallel-arm placebo-controlled 28-week clinical trial, comparing changes related to active drug (Qsymia®) vs. placebo (matched capsules). primaryPurpose: TREATMENT masking: QUADRUPLE maskingDescription: Eligible subjects will be assigned treatment using a sex-stratified permuted-block randomization (1:1) to drug vs. placebo for 27 weeks with varying block sizes constructed by the study statistician. whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 24 type: ESTIMATED name: Phentermine / Topiramate Extended Release Oral Capsule [Qsymia] name: Placebo measure: Treatment-emergent adverse events measure: Maximum tolerated dose measure: % change in BMI measure: Proportion of individuals who experience 5% decrease in BMI measure: Proportion of individuals who experience 2.5% decrease in BMI measure: Change in body fat mass measure: Change in visceral fat mass measure: Change in hunger measure: Change in energy intake sex: ALL minimumAge: 12 Years maximumAge: 28 Years stdAges: CHILD stdAges: ADULT facility: The Children's Hospital of Philadelphia city: Philadelphia state: Pennsylvania zip: 19104 country: United States lat: 39.95233 lon: -75.16379 facility: Seattle Children's city: Seattle state: Washington zip: 98101 country: United States name: Clinton Elfers role: CONTACT phone: 513-290-5710 email: clinton.elfers@seattlechildrens.org lat: 47.60621 lon: -122.33207 hasResults: False
nctId: NCT06299878 id: MelPRO-0322 briefTitle: MelPRO-0322 (CRISTINA Trial) [miCrobiome pRedIctS aPD1 effecTivnes In melaNoma pAtietns] acronym: CRISTINA overallStatus: RECRUITING date: 2022-01-01 date: 2024-12-31 date: 2025-07-01 date: 2024-03-08 date: 2024-03-08 name: Russian Academy of Medical Sciences class: OTHER briefSummary: The goal of this observational study is to learn about if new biomarkers such as gut microbiota and molecular genetics melanoma features could predict clinical radiological and pathological response to neoadjuvant monotherapy with anti-PD1 agents in patients with resectable stage IIIB-D melanoma. The main questions it aims to answer are:
After sugery adjuvant therapy will be prescribed for 12 month and patients will be followed up according to institutional routine practice for 5 years. conditions: Melanoma, Skin conditions: Melanoma Stage Iii studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: PROSPECTIVE count: 72 type: ESTIMATED name: Gut microbiota analysis measure: 2-year disease-free survival measure: pathological response rate measure: biomarker reproducibility sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: N.N. Blokhin Russian Cancer Research Center, skin tumor department status: RECRUITING city: Moscow zip: 115478 country: Russian Federation name: Igor V Samoylenko, MD, PhD role: CONTACT phone: +7 (499) 444-24-24 email: i.samoylenko@ronc.ru name: Angelina O Kuzmenko, MD role: CONTACT phone: +74993249024 email: angelin.kuzmenko@gmail.com name: Igor V Samoylenko, MD, PhD role: PRINCIPAL_INVESTIGATOR lat: 55.75222 lon: 37.61556 hasResults: False
nctId: NCT06299865 id: YXLL-KY-2023（150） briefTitle: Comparison of Detection Rates Between Two Commonly Used Bone Density Measurement Methods overallStatus: NOT_YET_RECRUITING date: 2024-03-01 date: 2024-12-31 date: 2024-12-31 date: 2024-03-08 date: 2024-03-08 name: Xiaoqian Zhang class: OTHER briefSummary: 72 adult patients who underwent lumbar spine anteroposterior DXA and QCT examinations at Qianfoshan Hospital in Shandong Province from January 2019 to December 2022 were selected, with an interval of no more than 3 months between the two examinations for the same patient.
4. Statistical analysis was conducted on the normal bone density, bone loss, and number of osteoporosis diagnosed by DXA and QCT respectively, in order to explore the differences in the detection rates of osteoporosis between these two monitoring methods. The data was analyzed and processed using SPSS 21.0 statistical software, and the count data was expressed as a rate (%) χ 2-test, P\<0.05 indicates statistically significant difference; Explore whether the difference in detection rates between the two is related to factors such as weight; Calculate the detection rates of osteoporosis using two detection methods in patients who have experienced brittle fractures, and preliminarily determine which detection method is more accurate in determining osteoporosis. conditions: Osteoporosis conditions: Diagnosis conditions: Dual Energy X-ray Absorptiometry conditions: Quantitative Computed Tomography studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: RETROSPECTIVE count: 72 type: ESTIMATED name: Ungrouped measure: Comparison of the difference in detection rates of osteoporosis between dual energy X-ray and quantitative CT sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Shandong Provincial Qianfoshan Hospital city: Jinan state: Shandong country: China lat: 36.66833 lon: 116.99722 hasResults: False
nctId: NCT06299852 id: TK01 briefTitle: Stereotactic Radiation Therapy for HE2-positive Oligometastatic Breast Cancer overallStatus: RECRUITING date: 2022-07-01 date: 2025-09-01 date: 2025-09-01 date: 2024-03-08 date: 2024-03-08 name: N.N. Petrov National Medical Research Center of Oncology class: OTHER briefSummary: This study involves two non-randomized groups of patients: the observation group and the comparison group. The comparison group will retrospectively include data on 29 patients with oligometastatic HER2-positive breast cancer who received treatment with trastuzumab-emtansine and had a history of SRT.
The combined effect of stereotactic radiation therapy on a metastatic lesion followed by anti-HER2 therapy in the 2nd line - trastuzumab emtansine, remains unexplored. This study plans to evaluate the effectiveness of combining systemic therapy and local control methods (SRT) in patients with oligometastatic HER2-positive breast cancer. It will be the first time the efficacy and toxic profile of this new combined treatment method in this patient population will be studied. This basket trial evaluates trastuzumab emtansine for oligo-metastatic breast cancer with the aim of inducing deep responses, long-lasting disease remissions, and potentially cure. conditions: HER2-positive Metastatic Breast Cancer conditions: Oligometastatic Disease studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: INVESTIGATOR count: 58 type: ESTIMATED name: Trastuzumab emtansine measure: Objective response rate (ORR) measure: Progression free survival (PFS) measure: Toxicity profile measure: Second co-primary outcome measure is quality of life sex: FEMALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: N.N. Petrov National Medical Research Center of Oncology status: RECRUITING city: Saint Petersburg country: Russian Federation name: Tatiana Semiglazova, DSc Med., Prof. role: CONTACT email: tsemiglazova@mail.ru name: Tatiana Kudryashova role: CONTACT phone: +79632165730 email: tatyana-kudryashova-98@mail.ru lat: 59.93863 lon: 30.31413 hasResults: False
nctId: NCT06299839 id: PAS-004-102 id: 2024-510900-34 type: EUDRACT_NUMBER briefTitle: PAS-004 in Patients With Advanced Solid Tumors overallStatus: RECRUITING date: 2024-02-29 date: 2025-12 date: 2027-02 date: 2024-03-08 date: 2024-03-08 name: Pasithea Therapeutics Corp. class: INDUSTRY briefSummary: The main purpose of this clinical trial is to test PAS-004 in people with advanced solid tumors with rat sarcoma virus (RAS), neurofibromatosis type I (NF1), or rapidly accelerated fibrosarcoma (RAF) mutations. The main questions it aims to answer are:
* The sponsors stops the study. conditions: RAS Mutation conditions: NF1 Mutation conditions: RAF Mutation conditions: Advanced Solid Tumors studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SEQUENTIAL interventionModelDescription: 3+3 dose expansion primaryPurpose: TREATMENT masking: NONE count: 42 type: ESTIMATED name: PAS-004 measure: Evaluation of dose limiting toxicities (DLTs) measure: Evaluation of adverse events (AEs) measure: Evaluation of AEs leading to discontinuation of investigational product (IP), PAS-004. measure: Evaluation of hematology laboratory parameters measure: Evaluation of clinical chemistry laboratory parameters measure: Apparent terminal elimination half-life (t1/2) in Plasma measure: Peak Plasma Concentration (Cmax) measure: Plasma predose or trough concentration (Ctau/Ctrough) measure: Time of maximum plasma concentration (Tmax) measure: Area under the concentration versus time curve from time zero to the last sampling time with quantifiable analyte (AUC0-t) measure: Area under the concentration versus time curve from time zero extrapolated to infinity if possible (AUC0-∞) measure: Area under the concentration versus time curve for the dosing interval, assuming steady state has been reached and duplicating the predose concentration for the 24 hour postdose concentration (AUC0-tau) measure: Apparent total plasma clearance if possible (CL/F) measure: Evaluation of the percentage of extracellular signal-regulated kinase phosphorylation (pERK) inhibition from baseline measure: Evaluation of the objective response rate (ORR) measure: Evaluation of progression-free survival (PFS) measure: Evaluation of overall survival (OS) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: NEXT Oncology status: RECRUITING city: Austin state: Texas zip: 78758 country: United States name: Erica Torres role: CONTACT phone: 210-610-5205 email: etorres@nextoncology.com lat: 30.26715 lon: -97.74306 facility: NEXT Oncology status: RECRUITING city: Irving state: Texas zip: 75039 country: United States name: Erica Torres role: CONTACT phone: 210-610-5205 email: etorres@nextoncology.com lat: 32.81402 lon: -96.94889 facility: NEXT Oncology status: RECRUITING city: San Antonio state: Texas zip: 78229 country: United States name: Carmen Gonzalez role: CONTACT phone: 210-580-9521 email: cgonzalez@nextoncology.com lat: 29.42412 lon: -98.49363 facility: NEXT Oncology status: RECRUITING city: Fairfax state: Virginia zip: 22031 country: United States name: Blake Patterson role: CONTACT phone: 703-783-4505 email: BPatterson@nextoncology.com lat: 38.84622 lon: -77.30637 hasResults: False
nctId: NCT06299826 id: D9090C00008 briefTitle: A Phase IIb Study of AZD5462 in Patients With Chronic Heart Failure acronym: LUMINARA overallStatus: NOT_YET_RECRUITING date: 2024-06-10 date: 2025-11-24 date: 2025-11-24 date: 2024-03-08 date: 2024-03-08 name: AstraZeneca class: INDUSTRY briefSummary: The main purpose of this study is to evaluate the effect of AZD5462 on cardiac function in participants with chronic heart failure (HF). conditions: Chronic Heart Failure studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 360 type: ESTIMATED name: AZD5462 name: Placebo measure: Cohort A and B: Change from Baseline in Ejection Fraction measure: Cohort A and B: Change from Baseline in Ejection Fraction measure: Cohorts A and B: Change from Baseline in Kansas City Cardiomyopathy Questionnaire overall summary score (KCCQ-OSS) measure: Cohorts A and B: Change from Baseline in New York Heart Association Functional Class (NYHA FC) measure: Cohorts A and B: Percentage Change from Baseline in cardiac biomarkers measure: Cohorts A and B : Plasma Concentration of AZD5462 measure: Cohorts A and B: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) sex: ALL minimumAge: 18 Years maximumAge: 85 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06299813 id: 771.284 id: 2022-002955-20 type: EUDRACT_NUMBER briefTitle: Effectiveness of a Single Dose of Betamethasone in Children With Symptomatic Adenovirus Infection acronym: Adeno-beta overallStatus: RECRUITING date: 2024-03-20 date: 2025-01-15 date: 2026-04-01 date: 2024-03-08 date: 2024-03-21 name: A.O.U. Città della Salute e della Scienza class: OTHER briefSummary: The goal of this double-blind, Placebo-controlled Randomized Study is to assess if a single dose of betamethasone in children with febrile adenoviral infection works well in achieving an early fever regulation.